Nivagen Pharmaceuticals Closes USD 16m Growth Equity Financing from Telegraph Hill Partners
20 May 2020 - - US-based specialty pharmaceuticals company Nivagen Pharmaceuticals, Inc has a USD 16m equity financing round led by life science venture capital and growth equity firm Telegraph Hill Partners, along with participation from existing investors, the company said.

Nivagen said it plans to use the proceeds for internal development and acquisition of additional generic and branded drugs to broaden its product portfolio.

The company is also exploring strategies to develop or acquire manufacturing facilities in the United States to help alleviate supply disruptions and accelerate time to market for its pipeline products.

Nivagen Pharmaceuticals is a specialty pharmaceuticals company engaged in the development and sale of difficult to formulate generic and branded prescription drugs for the North American market.

Nivagen is building a portfolio of high-quality, sustainable drug products by developing, acquiring, and in-licensing unique formulations to serve the needs of its customers.

Telegraph Hill Partners, founded in 2001 and based in San Francisco, CA, invests in commercial stage life science, medical technology and healthcare companies.